liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure - SIGNAL-HF (Swedish Intervention study - Guidelines and NT-proBNP AnaLysis in Heart Failure)
Danderyd Hospital.
Danderyd Hospital.
AstraZeneca Nord.
Nyby Primary Care Centre, Uppsala.
Show others and affiliations
2010 (English)In: European Journal of Heart Failure, ISSN 1388-9842, E-ISSN 1879-0844, Vol. 12, no 12, 1300-1308 p.Article in journal (Refereed) Published
Abstract [en]

Treatment of chronic heart failure (CHF) guided by natriuretic peptides has been studied in clinical trials with conflicting results. The aim of this study was to investigate if N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided therapy in symptomatic heart failure patients in primary care would improve clinical outcomes over and above treatment according to guidelines. SIGNAL-HF was a 9 month, randomized, single-blind, parallel group study in patients with CHF in NYHA class II-IV, ejection fraction (EF) less than 50% and elevated NT-proBNP levels (males greater than 800, females greater than 1000 ng/L). All investigators underwent a pre-study educational programme about current CHF guidelines. A control group managed by non-trained investigators was considered not possible for ethical and practical reasons. Patients were randomized to structured treatment of CHF according to guidelines with or without NT-proBNP monitoring. The choice and dose of therapy for CHF was at the investigators discretion. The primary outcome variable was the composite endpoint of days alive, days out of hospital, and symptom score from the Kansas City Cardiomyopathy Questionnaire. In all, 252 patients were randomized. The allocation groups were well balanced with regards to age, NT-proBNP, and EF. Treatment doses of beta-blockers and blockers of the renin-angiotensin-aldosterone system were markedly increased towards target doses and to a similar degree in both groups. There were no differences between the groups concerning either the primary endpoint (P = 0.28) or its components [cardiovascular (CV) death, P = 0.93; CV hospitalization, P = 0.88; or symptom score, P = 0.28]. NT-proBNP-guided CHF treatment did not result in important improvements in clinical outcomes in patients with CHF in primary care above and beyond what could be achieved by education and structured CHF treatment according to guidelines.

Place, publisher, year, edition, pages
Oxford University Press , 2010. Vol. 12, no 12, 1300-1308 p.
Keyword [en]
NT-proBNP; Chronic heart failure; RCT; Primary health care
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-63948DOI: 10.1093/eurjhf/hfq169ISI: 000284637400008OAI: diva2:384772
Available from: 2011-01-10 Created: 2011-01-10 Last updated: 2013-09-26

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Dahlström, Ulf
By organisation
Cardiology Faculty of Health SciencesDepartment of Cardiology
In the same journal
European Journal of Heart Failure
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 16 hits
ReferencesLink to record
Permanent link

Direct link